北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学医药卫生分析中心  > 期刊论文
学科主题: 公共卫生
题名:
Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy
作者: Dong, C.1,2; Liu, Z.1,2; Wang, F.1,2
关键词: Tumor ; radiotracer ; targeted therapy ; peptide receptor radionuclide therapy
刊名: CURRENT MEDICINAL CHEMISTRY
发表日期: 2014
卷: 21, 期:1, 页:139-152
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Biochemistry & Molecular Biology ; Chemistry, Medicinal ; Pharmacology & Pharmacy
研究领域[WOS]: Biochemistry & Molecular Biology ; Pharmacology & Pharmacy
关键词[WOS]: RECEPTOR RADIONUCLIDE THERAPY ; STIMULATING HORMONE PEPTIDE ; DISSEMINATED NEUROENDOCRINE TUMORS ; RADIOLABELED SOMATOSTATIN ANALOGS ; DUCTAL PANCREATIC ADENOCARCINOMA ; BETA-EMITTING RADIONUCLIDES ; IN-VIVO ; POSITIVE TUMORS ; PHASE-II ; MEDIATED RADIOTHERAPY
英文摘要:

A series of radiolabeled peptides have been designed and optimized for tumor-targeted peptide receptor radionuclide therapy (PRRT). Pre-clinical and clinical applications of PRRT have shown promising results on tumor response, overall survival, and quality of life in patients with several kinds of tumors. Y-90-DOTA-TOC and Lu-177-DOTA-TATE are two of the most common radiopharmaceuticals with symptomatic improvements and complete clinical data. In addition to somatostatin analogs, radiolabeled peptides have been developed to target the relative receptors overexpressed in the tumors, such as integrin alpha(v)beta(3), gastrin-releasing peptide receptor (GRPR), melanocortin-1 receptor (MC1-R), cholecystokinin (CCK) receptor, and glucagon-like peptide-1 receptor (GLP-1R). Several strategies have been designed to improve the therapeutic efficacy of PRRT. For instance, radiolabeled peptides could be optimized by the amino acid modification and radionuclide selection. Healthy tissue protective agents and multi-cycle procedures could effectively decrease the side effects of PRRT. Furthermore, combination treatments, including PRRT combined with surgery, chemotherapeutic agents, or radiosensitizing agents could be applied to increase the effectiveness of PRRT. In this review, the current progress of peptide-based radiopharmaceuticals for tumor-targeted PRRT was summarized. Radiopharmaceuticals currently under clinical investigation were also described.

语种: 英语
所属项目编号: 81125011 ; 81222019 ; 30930030 ; 81000625 ; 812011 27 ; 2013CB733802 ; 2011CB707703 ; 2011YQ030114 ; 2012ZX09102301-018 ; 2012 BAK25B03-16 ; 31300 ; BMU20110263 ; 7132131 ; 7132123 ; Z121107002512010
项目资助者: National Natural Science Foundation of China (NSFC) ; "973" projects ; Ministry of Science and Technology of China ; Ministry of Education of China ; Beijing Natural Science Foundation ; Beijing Nova Program
WOS记录号: WOS:000327778900010
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/56763
Appears in Collections:北京大学医药卫生分析中心_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Med Isotopes Res Ctr, Beijing 100191, Peoples R China
2.Peking Univ, Sch Basic Med Sci, Dept Radiat Med, Beijing 100191, Peoples R China

Recommended Citation:
Dong, C.,Liu, Z.,Wang, F.. Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy[J]. CURRENT MEDICINAL CHEMISTRY,2014,21(1):139-152.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Dong, C.]'s Articles
[Liu, Z.]'s Articles
[Wang, F.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Dong, C.]‘s Articles
[Liu, Z.]‘s Articles
[Wang, F.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2018  北京大学医学部 - Feedback
Powered by CSpace